Patents by Inventor Adeline Morel

Adeline Morel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9655897
    Abstract: The present invention relates to compounds of formula (I) wherein R, R1, X1 to X5 have the meaning as cited in the description and the claims. Said compounds are useful as TYK2 inhibitors for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immunologically-mediated diseases. The invention also relates to pharmaceutical compositions including said compounds as well as their use as medicaments.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: May 23, 2017
    Assignee: Cellzome Limited
    Inventors: Richard John Harrison, Nigel Ramsden, Jeremy Major, Adeline Morel, Laura Convery, Mihiro Sunose, Rosemary Lynch, Rita Adrego, Alison Jones
  • Publication number: 20160184307
    Abstract: The present invention relates to compounds of formula (I) wherein R, R1, X1 to X5 have the meaning as cited in the description and the claims. Said compounds are useful as TYK2 inhibitors for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immunologically-mediated diseases. The invention also relates to pharmaceutical compositions including said compounds as well as their use as medicaments.
    Type: Application
    Filed: March 3, 2016
    Publication date: June 30, 2016
    Inventors: Richard John HARRISON, Nigel RAMSDEN, Jeremy MAJOR, Adeline MOREL, Laura CONVERY, Mihiro SUNOSE, Rosemary LYNCH, Rita ADREGO, Alison JONES
  • Patent number: 9296725
    Abstract: The present invention relates to compounds of formula (I) wherein R, R1, X1 to X5 have the meaning as cited in the description and the claims. Said compounds are useful as TYK2 inhibitors for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immunologically-mediated diseases. The invention also relates to pharmaceutical compositions including said compounds as well as their use as medicaments.
    Type: Grant
    Filed: May 23, 2013
    Date of Patent: March 29, 2016
    Assignee: Cellzome Limited
    Inventors: Richard John Harrison, Nigel Ramsden, Jeremy Major, Adeline Morel, Laura Convery, Mihiro Sunose, Rosemary Lynch, Rita Adrego, Alison Jones
  • Patent number: 9175011
    Abstract: The invention relates to compounds of formula (I) wherein m, n, R1, T0 and T1 have the meaning as cited in the description and the claims. The compounds are useful as inhibitors of mTOR for the treatment or prophylaxis of mTOR related diseases and disorders. The invention also relates to pharmaceutical compositions including said compounds as well as methods of treating mTOR related diseases.
    Type: Grant
    Filed: September 21, 2012
    Date of Patent: November 3, 2015
    Assignee: CELLZONE LIMITED
    Inventors: Rosemary Lynch, Andrew David Cansfield, Daniel Paul Hardy, Mihiro Sunose, Adeline Morel, Laura Convery, Rita Adrego
  • Publication number: 20150166513
    Abstract: The present invention relates to compounds of formula (I) wherein R, R1, X1 to X5 have the meaning as cited in the description and the claims. Said compounds are useful as TYK2 inhibitors for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immunologically-mediated diseases. The invention also relates to pharmaceutical compositions including said compounds as well as their use as medicaments.
    Type: Application
    Filed: May 23, 2013
    Publication date: June 18, 2015
    Inventors: Richard John Harrison, Nigel Ramsden, Jeremy Major, Adeline Morel, Laura Convery, Mihiro Sunose, Rosemary Lynch, Rita Adrego, Alison Jones
  • Publication number: 20140378438
    Abstract: The invention relates to compounds of formula (I) wherein m, n, R1, T0 and T1 have the meaning as cited in the description and the claims. The compounds are useful as inhibitors of mTOR for the treatment or prophylaxis of mTOR related diseases and disorders. The invention also relates to pharmaceutical compositions including said compounds as well as methods of treating mTOR related diseases.
    Type: Application
    Filed: September 21, 2012
    Publication date: December 25, 2014
    Applicant: CELLZOME LIMITED
    Inventors: Rosemary Lynch, Andrew David Cansfield, Daniel Paul Hardy, Mihiro Sunose, Adeline Morel, Laura Convery, Rita Adrego
  • Publication number: 20120172384
    Abstract: The invention relates to compounds of formula (I) wherein R1 to R6 and T0 have the meaning as cited in the description and the claims. Said compounds are useful as inhibitors of ZAP-70, Syk or JAK3 for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, immunologically-mediated diseases. The invention also relates to pharmaceutical compositions including said compounds, the preparation of such compounds as well as the use as medicaments.
    Type: Application
    Filed: June 17, 2010
    Publication date: July 5, 2012
    Inventors: Mihiro Sunose, Jeremy Major, Richard John Harrison, Jay Freeman, Adeline Morel
  • Publication number: 20120142667
    Abstract: The invention relates to compounds of formula (I) wherein R1 to R5, X and X1 to X3 have the meaning as cited in the description and the claims. Said compounds are useful as inhibitors of ZAP-70 for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immunologically-mediated diseases. The invention also relates to pharmaceutical compositions including said compounds, the preparation of such compounds as well as the use as medicaments.
    Type: Application
    Filed: June 10, 2010
    Publication date: June 7, 2012
    Inventors: Nigel Ramsden, Jeremy Major, Adeline Morel, Mihiro Sunose, Nelly Piton